Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG-PLUS: Bisphosphonate or MMR to enhance BCG-induced trained immunity against COVID-19
2020-002456-21Phase 4Completed
- Sponsor
- Radboudumc
- Start
- May 2020
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bcg vaccine, alendronate and measles, mumps, and rubella vaccine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Radboudumc. Primary endpoint: Induction of trained immunity. Started May 2020; status: completed.
02
Drugs
bcg vaccinealendronatemeasles, mumps, and rubella vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002456-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002456-21.